NanoMedTrix is a clinical stage biotechnology company
developing nanoparticles to improve drug target
NanoMedTrix went from winning pitch competitions to winning multi-million dollar grants, with a little help from JPEC's Faculty Innovators program.
Eastern Iowa corridor spinoff continues to validate the clinical significance of the novel theranostic.
The funding supplements the NIH Phase II award, in particular commercialization efforts related to establishing a clinical trial network.
With a wide variety of biomedical applications, including delivering precise doses of tumoricidal drugs to target site and used as contrast agents for medical imaging.
A single dose is effective across 2 or more scanning types (PET, MRI , CT, Ultrasound), increasing efficiency and reducing multi scan/multi visit costs
Can work at cellular, tissue and organ level. Capable of targeting particular pathology or tissue type, thereby revolutionizing non invasive disease detection